Before I move on, here is a link to another video clip featuring Dr. Don Morris in Alberta, Canada:
But what about research featuring reovirus in the United States?
A engineered form of the reovirus, Reolysin, is already being tested on patients. Check-out this information I found about Reolysin on Oncolytics Biotech, Inc’s website:
REOLYSIN® is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus, which is widely found in the environment. By adulthood, most people have been exposed to the reovirus. The reovirus is non-pathogenic, which means that infections are typically asymptomatic. In clinical trials, REOLYSIN® has been shown to be well-tolerated, with patients exhibiting only mild, flu-like symptoms. REOLYSIN® has been used alone and in combination with chemotherapy and radiotherapy for various cancers, including head and neck cancers in an ongoing Phase III clinical trial.
REOLYSIN® is based upon research conducted by the Chief Operating Officer of Oncolytics, Dr. Matt Coffey. It was found that the reovirus was able to infect and selectively destroy cancer cells. When a normal cell is infected with the reovirus, an antiviral response is activated, which prevents the virus from replicating within the cell. However, inside a cancer cell with one or more mutations on a growth pathway called the Ras pathway, there is an aberrant antiviral response that is unable to prevent the virus from replicating. This abnormality allows the reovirus to multiply to an extent that is fatal to the cancer cell.
Here is the link to Oncolytics website: OncolyticsBiotech.com.
While most of the focus using Reolysin has been on other cancers, the site does list information about a Phase I study aimed at multiple myeloma:
Intravenous Administration of REOLYSIN® for Patients with Relapsed Multiple Myeloma
In May 2011, Oncolytics announced that the US National Cancer Institute (NCI) intended to conduct a Phase I study of REOLYSIN® alone in patients with relapsed multiple myeloma. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN®.
The primary endpoint for the dose escalation portion of this study will be adverse events using CTCAE criteria. Correlative studies will focus on the efficiency with which reovirus replicates in patient myeloma cells. Investigators will use standard cohorts-of-three Phase I dose escalation design with three to six patients being treated at each dose level. Secondary endpoints will include clinical benefit, duration of response and time to progression.
This company is apparently throwing everything at the wall to see what will stick. Oncolytics lists 31 different studies on their site.
I believe it’s a great thing that Canadian researchers are working with reovirus, too. Maybe they will discover a different wrinkle that might make a big difference. Either way, I just hope something works, don’t you?
Feel good and keep smiling! Pat